Abstract
Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Volume: 9 Issue: 2
Author(s): Tianfu Wu and Chandra Mohan
Affiliation:
Abstract: Autoimmunity affects a substantial fraction of our population. In patients with autoimmune disease, the immune system recognizes self-tissues as foreign. Common autoimmune diseases include rheumatoid arthritis, diabetes mellitus, lupus and multiple sclerosis. Though different target organs may be affected in different autoimmune diseases, aberrations in adaptive or innate immunity underlie all of these diseases. Abnormal functioning, differentiation and/or activation of T-cells, B-cells and myeloid cells have been documented in various autoimmune diseases. More recent studies have also detailed anomalous activation of various signaling axes including various MAPK, AKT, NF-κB, Bcl-2 family members, and JAK/STAT molecules in these cells, in the context of systemic autoimmunity. Among these, one molecular pathway that appears to be particularly attractive for therapeutic targeting is the PI3K/AKT/mTOR axis. In this review, we summarize how the AKT axis affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this axis in these diseases.
Export Options
About this article
Cite this article as:
Wu Tianfu and Mohan Chandra, The AKT Axis as a Therapeutic Target in Autoimmune Diseases, Endocrine, Metabolic & Immune Disorders - Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187153009788452417
DOI https://dx.doi.org/10.2174/187153009788452417 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fetal Mechanisms That Lead to Later Hypertension
Current Drug Targets Therapeutical Approaches of Vasoactive Intestinal Peptide as a Pleiotropic Immunomodulator
Current Pharmaceutical Design Homocysteine and Folate Therapy in Dialysis Patients
Letters in Drug Design & Discovery Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research New Perspectives on Acetaminophen
Current Cardiology Reviews Obesity and Asthma
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Editorial [ Has the Time Come for a New Definition of Microalbuminuria? ]
Current Vascular Pharmacology Rosuvastatin Induced Rhabdomyolysis in a Low Risk Patient: A Case Report and Review of the Literature
Current Clinical Pharmacology ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Ameliorative Potentials of Methanol Fractions of <i>Cnidoscolus aconitifolius</i> on Some Hematological and Biochemical Parameters in Streptozotocin Diabetic Rats
Endocrine, Metabolic & Immune Disorders - Drug Targets A New Insight of Herbal Promises Against Ocular Disorders: An Occuloinformatics Approach
Current Topics in Medicinal Chemistry The Impact of Depressive Symptoms on the Quality of Life of Patients with Type 2 Diabetes in Jazan Region, KSA
Current Diabetes Reviews NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Current Pharmaceutical Design Antidiabetic Properties of Medicinal Mushrooms with Special Reference to <i>Phellinus</i> Species: A Review
The Natural Products Journal Glucose Lowering Activity of Aqueous Ammodaucus leucotrichus Extract in Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets The Medicinal Chemistry of Genus <i>Aralia</i>
Current Topics in Medicinal Chemistry Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport
Current Molecular Medicine